Zimmer Highlights Acetabular System Portfolio at the 11th EFORT Congress in Madrid, Spain

Proven Fixation Technology and Advanced Bearing Options Combine to Better Match Individual Patient Demands

MADRID, June 3, 2010 - Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal
care, will be showcasing its extended Acetabular Cup portfolio at this year's
EFORT (European Federation of National Associations of Orthopaedics and
Traumatology) Congress in Madrid, Spain. The recently launched Zimmer
Allofit(R) IT, Continuum(TM) and Trilogy(R) IT Systems incorporate proven
fixation technologies and an integrated taper design that give surgeons the
ability to choose from a range of bearing options to better match the demands
of individual patients.

"Providing a more personalized fit to patients and increasing range of
motion are key points of emphasis in our acetabular offerings," said
Katarzyna Mazur, Senior Vice President, Sales and Marketing, EMEA and General
Manager, Zimmer GmbH. "The versatile nature of our Acetabular Cup portfolio
incorporates multiple cup liners to provide surgeons with the cup and bearing
options that best fit their individual patients' anatomy and lifestyles."

Hip replacement surgery patients represent diverse age groups and
lifestyles. As a result, surgeons need to consider a variety of implant
bearings to accommodate their patients' needs. Zimmer's 3-in-1 system of
bearing options is applicable for a wide range of clinical indications. The
Metasul(R) Liner incorporates Zimmer's Metasul Metal-on-Metal Technology
which provides stability and low wear and has more than twenty years of
successful clinical history. Longevity(R) Highly Crosslinked Polyethylene,
the principal technology behind the polyethylene liner, is highly resistant
to wear and aging with more than ten years of clinical experience. BIOLOX(R)
delta Ceramic Liner Technology provides excellent biocompatibility, low wear,
high hardness and good mechanical performance.

The Continuum Cup, recently launched globally, is made with Zimmer's
Trabecular Metal(TM) Technology, a highly porous tantalum material that
supports initial stability and long term biologic fixation. The Trilogy IT
Cup builds on the success of the Harris/Galante(TM) Porous and HGP II Cups by
combining proven features with new technology designed to inhibit the
formation and migration of polyethylene debris.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2009 sales were approximately US$4.1
billion. The Company is supported by the efforts of more than 8,000 employees
worldwide.

For more information about Zimmer, visit www.zimmer.com

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995
based on current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ
materially. For a list and description of such risks and uncertainties, see
our periodic reports filed with the U.S. Securities and Exchange Commission.
We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be set forth in our periodic reports.
Readers of this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

Media, Sabine Ciccotosto, +41(0)52-262-72-41, sabine.ciccotosto at zimmer.com; Investors: Paul Blair, +1-574-371-8042, paul.blair at zimmer.com; James T. Crines, +1-574-372-4264, james.crines at zimmer.com